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Abstract
Background. We aimed to evaluate the clinical outcomes of molecular glioblastoma (mGBM) as compared to histological GBM (hGBM) and to determine the prognostic impact of TERT mutation, EGFR amplification, and CDKN2A/B
deletion on isocitrate dehydrogenase (IDH)-wildtype GBM.
Methods. IDH-wildtype GBM patients treated with radiation therapy (RT) between 2012 and 2019 were retrospectively analyzed. mGBM was defined as grade II-III IDH-wildtype astrocytoma without histological features of GBM
but with one of the following molecular alterations: TERT mutation, EGFR amplification, or combination of whole
chromosome 7 gain and whole chromosome 10 loss. Overall survival (OS) and progression-free survival (PFS)
were calculated from RT and analyzed using the Kaplan–Meier method. Multivariable analysis (MVA) was performed using Cox regression to identify independent predictors of OS and PFS.
Results. Of the 367 eligible patients, the median follow-up was 11.7 months. mGBM and hGBM did not have significantly different OS (median: 16.6 vs 13.5 months, respectively, P = .16), nor PFS (median: 11.7 vs 7.3 months,
respectively, P = .08). However, mGBM was associated with better OS (hazard ratio [HR] 0.50, 95% CI 0.29–0.88)
and PFS (HR 0.43, 95% CI 0.26–0.72) than hGBM after adjusting for known prognostic factors on MVA. CDKN2A/B
deletion was associated with worse OS (HR 1.57, 95% CI 1.003–2.46) and PFS (HR 1.57, 95% CI 1.04–2.36) on MVA,
but TERT mutation and EGFR amplification were not.
Conclusion. Criteria for mGBM may require further refinement and validation. CDKN2A/B deletion, but not TERT
mutation or EGFR amplification, may be an independent prognostic biomarker for IDH-wildtype GBM patients.

Key Points
• Molecularly defined GBM based on the cIMPACT-NOW criteria has more favorable
prognosis than histological GBM.
• CDKN2A/B deletion predicts worse survival for IDH-wildtype GBM.
• TERT and EGFR alterations are not prognostic markers for IDH-wildtype GBM.
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This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
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Importance of the Study

Glioblastoma (GBM) is the most common malignant primary brain tumor with an exceedingly poor prognosis
despite multimodality treatment.1,2 It represents a heterogeneous entity with an expansive molecular and mutational
landscape.3 The recently updated World Health Organization
(WHO) classifications have now incorporated some of the
new molecular advances in their categorization and notably
distinguishes GBM by isocitrate dehydrogenase (IDH) mutation status.4 Significant advances in molecular and genetic techniques have allowed for the detailed analysis of
genomic alterations in GBM. These efforts have yielded an
emerging understanding of the dysregulating alterations in
3 key molecular signaling pathways, namely receptor tyrosine kinase/phosphoinositide 3-kinase (RTK/PI3K), p53, and
Rb, as obligatory events in GBM tumorigenesis.5,6 Further
gene expression–based molecular studies have facilitated
tumor classification into clinically relevant subtypes that
may exhibit distinct treatment response characteristics.7
Additional insight into somatic mutation profiles and
their impact on tumor behavior is necessary for diagnostic
clarity, prognostication, and identifying potential therapeutic targets. However, there is uncertainty regarding the
prognostic value of some of the most common genetic alterations in GBM, such as telomerase reverse transcriptase
(TERT) promoter mutation, epidermal growth factor receptor (EGFR) amplification, and cyclin-dependent kinase
inhibitor 2A/B (CDKN2A/B) deletion.8,9 CDKN2A/B deletion
appears prognostic for IDH-mutant astrocytoma,10,11 but
its impact on the clinical outcomes of IDH-wildtype GBM
has not been extensively investigated. The Consortium to
Inform Molecular and Practical Approaches to CNS Tumor
Taxonomy (cIMPACT-NOW) recently proposed a diagnostic entity of grade II-III IDH-wildtype astrocytoma that
should behave similarly as histological GBM (hGBM): diffuse astrocytic glioma, IDH-wildtype with molecular features of glioblastoma, WHO grade IV (referred hereafter
as molecular GBM). The molecular features defining this
new tumor entity include TERT mutation, EGFR amplification, or a combination of whole chromosome 7 gain and
whole chromosome 10 loss.12 However, because grade II-III
astrocytomas were not uniformly treated as aggressively

and this molecularly defined GBM entity
among IDH-wildtype GBM. Our results demonstrated that the molecularly defined GBM
had better survival compared with histologic
GBM when adjusted for other clinical or treatment factors. Moreover, we demonstrated that
homozygous CDKN2A/B deletion was an independently prognostic biomarker for worse survival among IDH-wildtype GBM, whereas TERT
mutation and EGFR amplification were not. Our
data support additional clinical investigation to
validate CDKN2A/B deletion as a prognostic biomarker for IDH-wildtype GBM.

as GBM in the past, additional clinical data should validate
that molecular GBM (mGBM) has comparable clinical outcomes to hGBM after modern chemoradiotherapy.
To address the above questions, this retrospective
study aims to leverage our large institutional data to
evaluate the clinical outcomes of mGBM as compared
to hGBM and to elucidate the prognostic impact of TERT
mutation, EGFR amplification, and CDKN2A/B deletion on
IDH-wildtype GBM.

Methods
Patient Population
Adult patients aged 18 years and older with newly diagnosed WHO grade IV IDH-wildtype supratentorial hGBM or
mGBM who were treated with at least one fraction of radiation therapy (RT) with or without chemotherapy at our
tertiary cancer center from July 2012 to July 2019 were retrospectively reviewed. mGBM was defined as histological
grade II-III IDH-wildtype astrocytoma with at least 1 of the
following molecular alterations: TERT promoter mutation,
EGFR amplification, or a combination of whole chromosome 7 gain and whole chromosome 10 loss in concordance with a recently published recommended diagnostic
criteria.12 Patients were required to have known O6methylguanine–DNA methyltransferase (MGMT) promoter
methylation status. Exclusion criteria included known IDH
mutation, H3 K27M mutation, leptomeningeal disease,
gliomatosis, or infratentorial disease in the brainstem or
cerebellum. The start date from July 2012 was chosen for
analysis as that was when routine testing of MGMT and
IDH become our institutional practice. The study was conducted with the approval of the institutional review board.

Pathologic and Molecular Analysis
All tumor specimens were evaluated by the institutional
board–certified neuropathologists. IDH mutation status
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Molecular and genomic-profiling techniques
have improved our understanding of glioblastoma (GBM). Common genetic alterations in
GBM include TERT mutation, EGFR amplification, and CDKN2A/B deletion, but their clinical
impact remains unclear. A recently proposed
consensus statement from the cIMPACT-NOW
committee has defined a new diagnostic entity termed as “diffuse astrocytic glioma, IDHwildtype with molecular features of GBM,
WHO grade IV.” We performed this large institutional study to evaluate the prognostic impact of these common molecular alterations
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Extent of resection (EOR) was classified into the following
3 categories: biopsy, subtotal resection (STR), and grosstotal/near-total resection (GTR) based on operative report
and postoperative MRI as previously described.16 Patients
received either standard-course RT (SRT) over approximately 6 weeks or short-course hypofractionated RT (HFRT)
as previously described.17,18 Patients treated with doseescalation protocols with a simultaneous boost with fractional dose > 2 Gy/day to a subregion as part of a 6-week RT
course, such as on the NRG-BN001 study (NCT02179086),
were included in the SRT cohort, as were patients who
started on SRT but did not complete or switched to HFRT.
Concurrent TMZ at a dose of 75 mg/m2 was given daily
during RT. Adjuvant TMZ was typically initiated 4–6 weeks
after completion of RT and administered orally at a dose of
150–200 mg/m2 given on days 1–5 per 28-day cycle for 6–12
cycles at the discretion of the neuro-oncologists.

Statistics
Patient and treatment characteristics were compared using
Fisher’s exact test for categorical variables and Mann–
Whitney U test for continuous variables. Overall survival
(OS) and progression-free survival (PFS) were calculated
using the Kaplan–Meier method and compared using the

Results
Patient Characteristics
Among 466 patients screened during the study period,
a total of 367 adult patients with newly diagnosed
supratentorial/nonmetastatic histological GBM (hGBM)
or molecular GBM (mGBM) met the eligibility criteria and
were included in this study. The following patients were
excluded from analysis: 57 patients with unknown MGMT
status, 26 patients with IDH-mutant GBM, 12 patients with
leptomeningeal disease or gliomatosis, 3 infratentorial
GBM, and 1 K27M-mutant diffuse midline glioma. Table 1
lists patient and treatment characteristics for the entire cohort and separately for the hGBM and mGBM subsets. The
median age was 60, and the median KPS was 80. The majority of patients had GTR (50%), harbored unmethylated
MGMT (63%), treated with SRT (84%), and received TMZ
(89%). The median SRT dose was 60 Gy, and the median
HFRT dose was 40 Gy. Of the 328 patients who received
TMZ, 327 (99.9%) received concurrent TMZ as per the
Stupp protocol, and only 1 case received adjuvant TMZ
after RT alone because he was on a protocol that omitted
concurrent TMZ. Overall, 350 of them (95%) were confirmed to be IDH-wildtype on immunohistochemistry or
NGS, and the remaining 17 cases were all hGBM who had
no known IDH mutation but also lacked information on
TERT mutation, EGFR amplification, and CDKN2A/B deletion status. NGS was performed on tumor specimens
from 150 patients using F1CDx and on additional 46 cases
using GPS. Overall, TERT mutation was evaluated using
NGS for 184 cases (150 using F1CDx and 34 using GPS);
EGFR amplification was evaluated for 277 cases (22 with
FISH alone, 150 with F1CDx NGS alone, and 105 with both
FISH and NGS); and CDKN2A/B deletion was evaluated for
150 cases using F1CDx NGS. Of the 105 patients who had
evaluation of EGFR amplification by both FISH and NGS,
98% had identical results, with only 2 cases that were positive on FISH but not on NGS (both are counted as positive
for the analysis). Of the 93 cases with CDKN2A/B deletion,
90 had deletions of both CDKN2A and CDKN2B, while 3
had CDKN2A deletion only. Twenty-two patients (6%) had
mGBM (7 patients with grade II and 15 patients with grade
III astrocytoma based on the 2016 WHO grading criteria).
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Treatments

log-rank test. All time-to-event data were calculated from
the start of RT. Univariable analysis (UVA) and multivariable
analysis (MVA) were performed using the Cox proportional
hazards regression model to identify prognostic factors associated with survival outcomes. Proportional hazard assumptions of each variable were checked graphically by
using a log-log survival plot. Variables with P less than .20
on UVA and well-established prognostic factors for survival were entered into the MVA. For the biomarkers that
were not available for the entire cohort, they were not entered for the MVA of the entire cohort but were analyzed
separately for the subset analyses. All statistical tests
were 2 sided. Statistical analyses were performed with the
Statistical Package for Social Sciences, version 23.0 (IBM
SPSS Statistics).

Neuro-Oncology
Advances

was assessed by immunohistochemistry to detect IDH1R132H mutation or next-generation sequencing (NGS) to
assess for variants in IDH1 or IDH2 genes. EGFR amplification was identified via fluorescence in situ hybridization (FISH) and/or NGS. EGFR amplification on FISH was
defined if the EGFR probe to chromosome 7 probe ratio
≥ 2.013,14 and was considered the gold standard if yielded
the discrepant result as compared to NGS.15 TERT mutation and homozygous CDKN2A/B deletion were only
evaluated by NGS. NGS was mostly performed using the
commercial Foundation one CDx test (F1CDx, Foundation
Medicine), which is a Clinical Laboratory Improvement
Amendments (CLIA)-certified NGS diagnostic test to
detect substitutions, insertions, deletions, and copy
number alterations in 324 genes and select gene rearrangements using DNA isolated from formalin-fixed
paraffin-embedded (FFPE) tumor tissue specimens. It is
an FDA-approved tissue-based companion diagnostic
test for tumor mutation profiling to be used by qualified health care professionals (https://www.accessdata.
fda.gov/cdrh_docs/pdf17/P170019C.pdf). Some patients
had a CLIA-certified institutional NGS panel called GPS
test (https://gps.wustl.edu/wp-content/uploads/2015/11/
CNS_tumor_info_card_UTD.pdf) that used targeted hybridization capture coupled with NGS of tumor-derived
genomic DNA from FFPE tissues to evaluate 24 genes
commonly involved in CNS tumors, including IDH1/2
and TERT mutations, but it did not evaluate EGFR amplification nor CDKN2A/B loss. TERT mutation, EGFR amplification, and CDKN2A/B deletion status were obtained
based on the analysis of the tumor samples at the initial
diagnosis.
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Table 1.

Patient and Treatment Characteristics

Characteristics

All (n = 367)

hGBM
mGBM

hGBM (n = 345)

mGBM (n = 22)

P Value

—

—

—

345 (94)
22 (6)

Age at diagnosis (y), median (range)

60 (21–86)

60 (21–86)

62.5 (37–80)

.97

KPS, median (range)

80 (30–100)

80 (40–100)

90 (30–100)

.06
.66

Sex, n (%)
Male

219 (60)

207 (60)

12 (55)

Female

148 (40)

138 (40)

10 (45)

Race, n (%)
White

344 (94)

324 (94)

20 (91)

Other

23 (6)

21 (6)

2 (9)

182 (50)

177 (51)

5 (23)

.64

Extent of resection, n (%)
GTR
STR

99 (27)

95 (28)

4 (18)

Biopsy

86 (23)

73 (21)

13 (59)

<.01

MGMT methylation, n (%)
Yes

135 (37)

128 (37)

7 (32)

No

232 (63)

217 (63)

15 (68)

.82

RT type, n (%)
SRT

307 (84)

287 (83)

20 (91)

HFRT

60 (16)

58 (17)

2 (9)

.55

TMZ chemotherapy
Yes

328 (89)

308 (89)

20 (91)

No

39 (11)

37 (11)

2 (9)

1.00

TERT mutation by NGS, n (%)
Yes

167 (91)

151 (90)

16 (94)

No

17 (9)

16 (10)

1 (6)

Unknown

183
118 (43)

112 (44)

6 (29)

No

159 (57)

144 (56)

15 (71)

Unknown

90

1.00

EGFR amplification by FISH or NGS
Yes

.25

CDKN2A/B deletion by NGS
Yes

93 (62)

87 (64)

6 (40)

No

57 (38)

48 (36)

9 (60)

Unknown
Somatic mutations of the 3 canonical pathways

.09

217
a

Three pathways

130 (87)

119 (88)

11 (73)

Two pathways

13 (9)

10 (7)

3 (20)

One pathway

7 (5)

6 (4)

1 (7)

Unknown

217

.23

FISH, fluorescence in situ hybridization; GTR, gross-total/near-total resection; HFRT, short-course hypofractionated RT; hGBM, histological GBM;
mGBM, molecular glioblastoma; NGS, next-generation sequencing; RT, radiation therapy; SRT, standard-course RT; STR, subtotal resection; TMZ,
temozolomide.
aSomatic mutations affecting PI3K/MAPK, p53, or Rb pathways as detected on a commercial NGS of 324 gene panel.
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After a median follow-up of 11.7 months, the median OS
and PFS for the entire cohort were 13.9 months (95%
CI 12.2–15.6) and 7.5 months (95% CI 6.8–8.3), respectively. Patients with mGBM had nonsignificantly higher
OS (median: 16.6 vs 13.5 months, respectively, P = .16;
Figure 1A) and PFS (median: 11.7 vs 7.3 months, respectively, P = .08; Figure 1B) as compared to patients with
hGBM. When evaluating a more homogeneous subset of
patients who received SRT and TMZ, similar trend was observed between mGBM and hGBM for OS (median: 16.6 vs
15.6 months, respectively, P = .49; Figure 1C) and PFS (median: 12.4 vs 7.7 months, respectively, P = .17; Figure 1D).
The reason that the survival curves of mGBM and hGBM
after SRT+TMZ appeared closer was likely due to selection bias in clinical practice: More clinically aggressive

60

hGBM

40
20
0
0

6

No. at risk:
hGBM: 345
mGBM: 22

260
18

C

12
Time (mos)
166
11

Overall survival (%)

60

No. at risk:
hGBM: 345
mGBM: 22

187
17

20
0

221
17

150
10

0

59
5

hGBM with SRT+TMZ

No. at risk:
hGBM: 270
mGBM: 19

hGBM

20

98
6

40

12
Time (mos)

40

6

mGBM with SRT+TMZ

6

mGBM

60

0

P = .49

0

P = .08

80

24

100
80
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18

D

Progression-free survival (%)

Overall survival (%)

80

B
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mGBM

Progression-free survival (%)
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A
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Time (mos)
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24
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3
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0
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0
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5
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165
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122
9

18

24

44
2

23
2

Figure 1. Survival outcomes of patients stratified by molecular glioblastoma (mGBM) and histological GBM (hGBM) status. (A) Overall survival
(OS) of the entire study cohort. (B) Progression-free survival (PFS) of the entire study cohort. (C) OS of the subset receiving standard-course radiation therapy (SRT) and temozolomide (TMZ). (D) PFS of the subset receiving SRT and TMZ.
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Comparison of Molecular and Histological GBM
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mGBM (higher grade or larger tumor burden IDH-wildtype
astrocytomas) were historically treated with standard
chemoradiotherapy, whereas better prognostic hGBM
(younger patients with better KPS) received standard
chemoradiotherapy. As given in Table 1, the mGBM cohort
had a lower proportion of GTR, a nonsignificantly higher
KPS, and a nonsignificantly lower proportion of CDKN2A/B
deletion when compared with the hGBM cohort. On MVA,
mGBM was associated with improved OS (hazard ratio [HR]
0.50, 95% CI 0.29–0.88) and PFS (HR 0.43, 95% CI 0.26–0.72)
relative to hGBM after adjusting for known prognostic factors (Table 2; Supplementary Table S1). Interestingly, age
lost its significance for OS and PFS on MVA, likely due to
its correlation with the use of HFRT and TMZ, which are the
2 treatment factors included in the multivariable models.
Similar results were also obtained using MVA with a more
homogenous subset of patients treated with SRT and TMZ
(data not shown). Of note, the OS and PFS between mGBM
with histological grade II versus grade III astrocytoma were
similar (data not shown). One mGBM patient with histological grade II astrocytoma and TERT mutation is still alive
at 62 months, and he was treated with subtotal resection
followed by RT alone without chemotherapy.

There were 26 other supratentorial/nonmetastatic IDHwildtype grade II–III astrocytoma cases during the study
period: 12 were evaluated but did not have any of the molecular alterations of mGBM, and the remaining 14 cases
were not evaluated.
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Table 2.

Univariable and Multivariable Analysis for OS

Characteristics

UVA

MVA

1.02 (1.01–1.03)

<.001

1.00 (0.99–1.02)

P Value
.39

KPS

0.97 (0.96–0.98)

<.001

0.98 (0.97–0.99)

.001

Male sex

1.03 (0.82–1.21)

.78

—

—

Non-White race

1.07 (0.65–1.77)

.80

—

—

mGBM (vs hGBM)

0.68 (0.40–1.17)

.16

0.50 (0.29–0.88)

.02

.002

1.66 (1.24–2.22)

.001

Extent of resection
GTR

Ref

STR
Biopsy

1.56 (1.18–2.06)
3.264 (2.42–4.40)

<.001

3.05 (2.22–4.17)

<.001

Unmethylated MGMT

1.79 (1.39–2.30)

<.001

1.81 (1.40–2.35)

<.001

HFRT

2.48 (1.83–3.37)

<.001

1.53 (1.04–2.24)

.03

No TMZ chemotherapy

2.68 (1.86–3.85)

<.001

1.61 (1.07–2.41)

.02

TERT mutation (n = 184)

1.14 (0.64–2.03)

.67

—

—

EGFR amplification by FISH or NGS (n = 277)

1.21 (0.92–1.58)

.18

—

—

CDKN2A/B deletion by NGS (n = 150)

1.46 (0.96–2.21)

.08

—

—

—

—

Pathways affected
Three pathways

Ref

Two pathways

0.71 (0.33–1.53)

.38

One pathway

0.32 (0.08–1.28)

.11

FISH, fluorescence in situ hybridization; GTR, gross-total/near-total resection; HFRT, short-course hypofractionated radiation therapy; hGBM,
histological GBM; mGBM, molecular glioblastoma; MVA, multivariable analysis; NGS, next-generation sequencing; STR, subtotal resection; TMZ,
temozolomide; UVA, univariable analysis.

  
Prognostic Impact of TERT Mutation, EGFR
Amplification, and CDKN2A/B Deletion
As given in Table 2 and Supplementary Table S1, TERT mutation, EGFR amplification, and CDKN2A/B deletion were
not significantly associated with different OS, nor for PFS
on UVA. Because these 3 biomarkers were not uniformly
tested for the entire cohort, each variable was evaluated
separately in the subset of patients with available information on their mutation status. On MVA, CDKN2A/B deletion
was associated with worse OS (HR 1.57, 95% CI 1.003–2.46)
and PFS (HR 1.57, 95% CI 1.04–2.36) after adjusting for other
known prognostic factors including MGMT methylation
(Table 3). However, TERT mutation and EGFR amplification were not significantly associated with different OS,
nor PFS on MVAs (Supplementary Tables S2–S3). There
was no significant interaction between MGMT methylation
and TERT mutation for OS or PFS (data not shown). To reduce the effect of heterogeneous treatment and potentially
more favorable outcomes of mGBM, the MVA was then repeated using a subset of 107 hGBM patients with available
CDKN2A/B status who received SRT and TMZ. In the subset
analysis, CDKN2A/B deletion was again associated with
significantly worse OS (HR 1.93, 95% CI 1.08–3.43) and PFS
(HR 2.02, 95% CI 1.20–3.41; Table 4). As shown in Figure 2A
and B, among the entire cohort, CDKN2A/B deletion was
associated with nonsignificantly worse OS (median: 11.1
vs 14.3 months, respectively, P = .07) and PFS (median:
6.0 vs 8.7 months, respectively, P = .11) as compared to

CDKN2A/B wildtype. However, in the more homogenous
subset of hGBM patients who received SRT and TMZ,
CDKN2A/B deletion was associated with statistically worse
OS (median: 11.3 vs 16.9 months, respectively, P = 0.047;
Figure 2C) and PFS (median: 6.9 vs 10.2 months, respectively, P = .03; Figure 2D). Interestingly, even in the subset
analyses, mGBM was associated with more favorable OS
and PFS than hGBM when adjusted for CDKN2A/B deletion, TERT mutation, or EGFR amplification status (Table 3;
Supplementary Tables S2–S3). Because 150 patients had
a more comprehensive NGS panel of 324 genes using
F1CDx, their mutation profiles were reviewed and categorized by alterations in the 3 canonical pathways (RTK/PI3K,
p53, and Rb). Interestingly, the majority of patients had
somatic mutations in all 3 pathways (87%), with relatively
few cases with alterations in only one pathway (5%). The
number of pathways involved was not significantly associated with OS, nor PFS on UVA (Table 2; Supplementary
Table S1).

Discussion
This study demonstrates that the newly defined entity
of mGBM, formally known as “diffuse astrocytic glioma,
IDH-wildtype with molecular features of glioblastoma,
WHO grade IV,” likely comprises of a small proportion of
all IDH-wildtype GBM and may have slightly better clinical
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Multivariable Analysis of OS and PFS for All Patients with Known CDKN2A/B Deletion Status (n = 150)
OS
1.00 (0.98–1.02)

P Value
.90

PFS
1.00 (0.98–1.02)

P Value
.85

KPS

0.98 (0.96–0.995)

.009

0.98 (0.96–0.99)

.001

mGBM

0.54 (0.25–1.18)

.12

0.46 (0.23–0.92)

.03

Extent of resection
GTR

Ref

STR

1.88 (1.08–3.27)

.03

2.23 (1.38–3.61)

.001

Biopsy

3.00 (1.79–5.03)

<.001

3.93 (2.38–6.50)

<.001

Unmethylated MGMT

1.82 (1.12–2.96)

.02

2.87 (1.80–4.58)

<.001

HFRT

2.40 (1.23–4.67)

.01

1.39 (0.76–2.56)

.29

No TMZ chemotherapy

1.28 (0.66–2.47)

.46

1.16 (0.63–2.15)

.64

CDKN2A/B deletion by NGS

1.57 (1.003–2.46)

.048

1.57 (1.04–2.36)

.03

FISH, fluorescence in situ hybridization; GTR, gross-total/near-total resection; HFRT, short-course hypofractionated radiation therapy; hGBM, histological GBM; mGBM, molecular glioblastoma; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; STR, subtotal
resection; TMZ, temozolomide.

  
  
Table 4.

Multivariable Analysis of OS and PFS for hGBM Patients s/p SRT and TMZ with Known CDKN2A/B Deletion Status (n = 107)

Characteristics

OS

P Value

PFS

P Value

Age at diagnosis

0.99 (0.97–1.02)

.43

0.99 (0.97–1.01)

.36

KPS

0.96 (0.94–0.99)

.001

0.95 (0.94–0.97)

<.001

Extent of resection
GTR

Ref

STR

1.48 (0.76–2.88)

.25

2.00 (1.14–3.50)

Ref
.02

Biopsy

2.79 (1.48–5.25)

.001

3.63 (1.97–6.70)

<.001

Unmethylated MGMT

1.59 (0.90–2.83)

.11

2.85 (1.66–4.87)

<.001

CDKN2A/B deletion by NGS

1.93 (1.08–3.43)

.03

2.02 (1.20–3.41)

.008

GTR, gross-total/near-total resection; hGBM, histological GBM; mGBM, molecular glioblastoma; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; SRT, standard-course RT; STR, subtotal resection; TMZ, temozolomide.

  
outcomes than histological IDH-wildtype GBM when adjusted for known prognostic factors. Although TERT promoter mutation and EGFR amplification may be common
canonical alterations for IDH-wildtype GBM that may guide
diagnosis and define mGBM, they do not appear prognostic for established IDH-wildtype GBM cases. In contrast, CDKN2A/B deletion appears to be an independent
prognostic biomarker for IDH-wildtype GBM.
IDH-wildtype gliomas are known to harbor a worse
prognosis than their IDH-mutant counterparts,19 with
some studies suggesting that most histological grade
II-III IDH-wildtype astrocytomas may represent unrecognized GBM when subjected to further molecular and
genomic-profiling techniques.20,21 These tumors demonstrate heterogeneous clinical behavior, which necessitates
the development of additional markers for further stratification.22 The cIMPACT-NOW consortium attempted to address this need by proposing guidelines for identifying
mGBM based on published literature, suggesting shortened survival for IDH-wildtype grade II-III astrocytomas
carrying certain alterations.12,22–25 The median OS of

16.6 months exhibited by mGBM in the present report
was comparable to that of a previously published cohort
of IDH-wildtype grade II-III gliomas with EGFR amplification or TERT mutation.22 Similarly, Reuss et al. previously
reported a median OS of 19.4 months for 124 lower grade
astrocytoma cases with molecularly integrated GBM diagnosis based on methylation and copy number profiles as
well as incorporating information on TERT mutation, EGFR
amplification, chromosome 7p gain and 10q loss, or combined chromosome 10q/13q/14q deletion.21 Given the median OS of these patients is only a few months better than
hGBM, our study supports that they should be treated aggressively as hGBM. However, after adjusting for known
prognostic and treatment factors using MVA, our study
also demonstrated that mGBM had significantly better OS
and PFS than hGBM. One explanation may be that mGBM
cases were diagnosed at a slightly earlier stage than their
hGBM counterparts, thus benefiting from lead-time bias.
A previous global DNA methylation profiling study of
a large cohort of brain tumors revealed that TERT mutation was the least specific parameter for GBM compared
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Figure 2. Survival outcomes of patients stratified by CDKN2A/B deletion status. (A) Overall survival (OS) of the entire study cohort. (B) Progressionfree survival (PFS) of the entire study cohort. (C) OS of the subset receiving standard-course radiation therapy (SRT) and temozolomide (TMZ). (D)
PFS of the subset receiving SRT and TMZ.
  

with EGFR amplification or whole chromosome 7 gain and
whole chromosome 10 loss, suggesting that TERT mutation alone may be an insufficient diagnostic marker of
GBM.26 Interesting, one of our mGBM patient with TERT
mutation alone had prolonged OS after RT without chemotherapy. Weller et al. previously analyzed a group of IDHwildtype grade II–III gliomas with GBM-like copy number
changes, primarily whole chromosome 7 gain and whole
chromosome 10 loss. This GBM-like group exhibited a
median PFS of 1.5 years and OS of 2.4 years, which compared more favorably to hGBM survival data, suggesting
that the chromosomal 7 and 10 changes alone may be inadequate to diagnose GBM.24 Additionally, a recent report
showed that TERT mutation conferred significantly different prognosis depending on the presence or absence
of whole chromosome 7 gain and whole chromosome 10
loss, suggesting that the presently utilized mGBM criteria
may be too heterogeneous.25 In contrast, Tesileanu et al.
recently compared 71 mGBM patients with 192 hGBM patients and observed similar OS. However, their mGBM cohort had significantly higher proportion of biopsy alone
(83% vs 17%, respectively, P < .001) and lower proportion

of chemoradiotherapy than the hGBM cohort (42% vs 90%,
respectively, p<0.001). Thus, the less intense treatment of
mGBM may have skewed their OS closer to hGBM. Indeed,
after adjusting for treatment imbalance on MVA in their
supplemental table, hGBM had borderline worse OS than
mGBM (HR 1.58, 95% CI 0.98–2.56; P = .06).27 Also, their
analysis did not evaluate MGMT status, which might have
further confounded their analysis. Thus, further validation
of the cIMPACT-NOW diagnostic guideline with a larger
cohort is necessary to assess whether these tumors truly
behave comparably to hGBM and whether refinement of
these molecular signatures may be required to diagnose
mGBM accurately.
Our study demonstrated that homozygous CDKN2A/B
deletion independently predicted for worse OS and PFS
among IDH-wildtype GBM. The prognostic significance
of CDKN2A/B deletion among IDH-wildtype GBM lacks
extensive investigation. The CDKN2A gene encodes for
the protein p14ARF that serves as a tumor suppressor
by stabilizing p53 function and cell cycle control. This
locus encodes an additional tumor suppressor protein in
p16INK4a that inhibits cyclin D to bind cyclin-dependent
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was not associated with OS, but they did not account for
MGMT status.39 Therefore, our study is consistent with the
majority of prior studies suggesting that TERT mutation
is not an independent prognostic factor for IDH-wildtype
GBM. Our study did not observe a significant interaction
between TERT mutation and MGMT methylation, which
might have been limited by the smaller sample size and
only 9% of our evaluable cohort being TERT-wildtype.
Similarly, EGFR amplification was also not a significant prognostic factor in this analysis. EGFR amplification
is one of the most common genetic aberrations in GBM,
which has garnered this gene locus significant attention
for both a possible molecular marker for tumor outcomes
and a potential target for treatment. EGFR amplification occurred in 44% of our cohort, which is consistent with previous genomic analyses reporting that approximately 50%
of GBMs harbored EGFR alterations.6 EGFR is a receptor tyrosine kinase that induces downstream signaling through
RTK/PI3K pathways, among others, to induce cellular differentiation and proliferation and play a causal role in tumorigenesis.40 Though hypothesized to serve as a potential
prognostic biomarker for GBM, there lacks a consensus
regarding the impact of EGFR amplification on clinical outcomes. Two recent meta-analyses of available EGFR outcomes literature have yielded different results.41,42 In the
meta-analysis by Chen et al., pooling data from 3 GBM
studies and 3 anaplastic astrocytoma studies from before
2010, they found no significant difference in OS between
those with positive or negative EGFR amplification.41 In
the second meta-analysis by Li et al., the authors pooled
10 GBM studies and reported that EGFR amplification
was associated with worse OS (pooled HR: 1.57, 95% CI
1.15–2.14), but 50% of their studies were again from before 2010.42 In both studies, IDH and MGMT status were
not accounted for, and the data were mostly from the time
before the wide use of TMZ. In an unselected population
without known IDH status, lack of EGFR amplification may
be a surrogate of an IDH-mutant glioma, which may lead to
the observation that a lack of EGFR amplification is associated with better prognosis. Given our study analyzed EGFR
amplification among 277 confirmed IDH-wildtype GBM
patients with known MGMT status treated in the modern
era, the negative finding suggests that EGFR amplification
is likely not a meaningful prognostic biomarker for IDHwildtype GBM. Interestingly, using 150 patients who had
NGS of 315 gene panel, we observed that 87% had mutations of all 3 canonical pathways (RTK/PI3K, p53, and Rb),
so EGFR amplification may be just one of many mechanisms for GBM tumorigenesis and thus may not carry any
prognostic impact.
Given the current study is retrospective and derives
from a single high-volume tertiary center, the findings
should be considered hypothesis-generating and should
be further validated. Given the relatively limited sample
size of our mGBM cohort, a more extensive study is required for validation, ideally with patients treated with
uniform chemoradiotherapy and known MGMT status.
Regarding CDKN2A/B deletion, it was only evaluated for
41% of cases in this study. CDKN2A/B testing was routinely evaluated as part of an NGS panel for the more recent patients and should not be influenced by selection
bias. However, validation from larger multi-institutional
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kinase 4 and 6, preventing the complex to phosphorylate
Rb and to promote G1 to S phase transition.28,29 Thus,
CDKN2A deletion promotes tumorigenesis via 2 of the
central somatic mutation pathways implicated in GBM
pathogenesis and is typically occurring in the presence
of CDKN2B deletion. In a genomic analysis of 251 GBMs
from The Cancer Genome Atlas (TCGA) Research Network,
58% of p53 pathway disruption occurred via CDKN2A deletion, and CDKN2A deletion was implicated in over 50%
of Rb function impairment.6 CDKN2A deletion was also associated with high proliferative indices and higher tumor
grade.30,31 In a previous molecular analysis comparing 2
age- and gender-matched groups of GBM with either long
or short period until tumor progression (>24 months vs
< 6 months), CDKN2A deletion status did not carry prognostic significance, but the study was small with only
21 patients for each group.32 Among a study of 105 primary gliomas encompassing grade I–IV astrocytomas,
oligoastrocytomas, and oligodendrogliomas, CDKN2A deletion was found to be associated with poor survival only
in the subgroup of GBM patients older than 50 years.31
The authors noted increasing rates of CDKN2A deletion
from low- to high-grade tumors, suggesting that CDKN2A
deletion represented a molecular change late in tumor
progression rather than in initiation. However, the study
was conducted before routine interrogation of IDH status
and included both IDH-mutant oligodendrogliomas and
astrocytomas along with IDH-wildtype GBM, which might
have confounded their analysis. Notably, 2 recent studies
reported that the CDKN2A deletion was prognostic for IDHmutant astrocytoma, which will be incorporated in the new
grading criteria.10,11 Our results suggest that CDKN2A/B
deletion may also be prognostic for IDH-wildtype GBM
and deserves further investigation.
TERT promoter mutation was not prognostic for OS and
PFS of IDH-wildtype GBM in our study, and we did not
observe a significant interaction between TERT mutation
and MGMT methylation. TERT mutation is typically observed in 70%–80% of GBM genomes and may represent
a mechanism by which these tumors perform telomere
elongation to achieve limitless replicative potential.33,34
Despite an emerging body of evidence characterizing the
functional role of TERT mutation and its possible clinical utility as a therapeutic target,33 there lacks an established consensus on its prognostic value for IDH-wildtype
GBM.34–36 Furthermore, multiple retrospective studies
have suggested that the clinical significance of the TERT
mutation may rely on the tumor genetic background, particularly that of MGMT methylation status.37–39 Arita et al.
analyzed 452 IDH-wildtype GBM patients (including 58%
TERT-mutant) and reported that TERT mutation was prognostic for OS and PFS. They also observed significant
interaction between TERT mutation and MGMT methylation, in which the clinical outcomes of TERT-mutant
versus TERT-wildtype differed depending on the MGMT
methylation status.38 In contrast, Nguyen et al. analyzed
303 IDH-wildtype GBM (including 75% TERT-mutant) and
did not observe significant association of TERT mutation
with OS and PFS. They also observed significant interaction between TERT mutation and MGMT methylation.37
Pekmezci et al. analyzed 309 IDH-wildtype GBM case (including 77% TERT-mutant) and reported TERT mutation
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studies is warranted to confirm its prognostic impact.
As mentioned earlier, given the relative rarity of TERTwildtype status, our study may be underpowered to detect a small prognostic impact. However, this would also
suggest that it is unlikely to have a significant impact on
patient stratification as the vast majority of GBM patients
will have TERT mutation. Our study purposely included
all GBM patients who received at least 1 fraction of RT
with or without TMZ to try to capture the real-world experience and to minimize selection bias. Subset analyses
with patients who received SRT and TMZ also showed the
same results, thus suggesting treatment heterogeneity
should not affect the main findings.
In summary, CDKN2A/B deletion, but not TERT mutation nor EGFR amplification, appears to be an independent prognostic biomarker for IDH-wildtype GBM.
Although mGBM based on the current cIMPACT-NOW
criteria has relatively poor OS and PFS, its clinical outcomes may not be identical to that of hGBM after
chemoradiotherapy, so further refinement and validation
may be needed.

Ma et al. Molecular biomarkers for IDH-wildtype glioblastoma

Downloaded from https://academic.oup.com/noa/article/2/1/vdaa126/5908751 by Washington University School of Medicine Library user on 19 December 2022

31. Labuhn M, Jones G, Speel EJ, et al. Quantitative real-time PCR does
not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
Oncogene. 2001;20(9):1103–1109.
32. Kraus JA, Glesmann N, Beck M, et al. Molecular analysis of the PTEN,
TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 2000;48(2):89–94.
33. Man RJ, Chen LW, Zhu HL. Telomerase inhibitors: a patent review (20102015). Expert Opin Ther Pat. 2016;26(6):679–688.
34. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups
based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J
Med. 2015;372(26):2499–2508.
35. Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of
TERT, EGFR, and IDH status defines distinct prognostic glioblastoma
classes. Neurology. 2014;83(13):1200–1206.
36. Simon M, Hosen I, Gousias K, et al. TERT promoter mutations: a novel
independent prognostic factor in primary glioblastomas. Neuro Oncol.
2015;17(1):45–52.
37. Nguyen HN, Lie A, Li T, et al. Human TERT promoter mutation enables
survival advantage from MGMT promoter methylation in IDH1 wild-type
primary glioblastoma treated by standard chemoradiotherapy. Neuro
Oncol. 2017;19(3):394–404.
38. Arita H, Yamasaki K, Matsushita Y, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol
Commun. 2016;4(1):79.
39. Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with
WHO 2016 integrated diagnosis: additional prognostic roles of ATRX
and TERT. Acta Neuropathol. 2017;133(6):1001–1016.
40. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354.
41. Chen JR, Xu HZ, Yao Y, Qin ZY. Prognostic value of epidermal growth
factor receptor amplification and EGFRvIII in glioblastoma: metaanalysis. Acta Neurol Scand. 2015;132(5):310–322.
42. Li J, Liang R, Song C, Xiang Y, Liu Y. Prognostic significance of epidermal
growth factor receptor expression in glioma patients. Onco Targets Ther.
2018;11:731–742.

Neuro-Oncology
Advances

20. Brat DJ, Verhaak RGW, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med.
2015;372(26):2481–2498.
21. Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas
biologically and clinically resolve into other tumor entities. Acta
Neuropathol. 2015;130(3):407–417.
22. Aibaidula A, Chan AK, Shi Z, et al. Adult IDH wild-type lowergrade gliomas should be further stratified. Neuro Oncol.
2017;19(10):1327–1337.
23. Aoki K, Nakamura H, Suzuki H, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol.
2018;20(1):66–77.
24. Weller M, Weber RG, Willscher E, et al. Molecular classification
of diffuse cerebral WHO grade II/III gliomas using genome- and
transcriptome-wide profiling improves stratification of prognostically
distinct patient groups. Acta Neuropathol. 2015;129(5):679–693.
25. Wijnenga MMJ, Dubbink HJ, French PJ, et al. Molecular and clinical
heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number
status allows superior prognostic stratification. Acta Neuropathol.
2017;134(6):957–959.
26. Stichel D, Ebrahimi A, Reuss D, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT
promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol.
2018;136(5):793–803.
27. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Neuro Oncol. 2020;22(4):515–523.
28. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
29. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators
of G1-phase progression. Genes Dev. 1999;13(12):1501–1512.
30. Ono Y, Tamiya T, Ichikawa T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
J Neuropathol Exp Neurol. 1996;55(10):1026–1031.

11

